(marketscreener.com) CASI’s pipeline expanded to include first-in-class monoclonal antibody developed to unlock anti-cancer immunity in liquid and solid tumors Collaboration accelerates and expands BioInvent’s global development plans for BI-1206 BioInvent to receive $12 million upfront… https://www.
